Supplementary Material

1 Supplementary Data

Search Strategy Used in Pubmed 2020/7/19

#1 Stomach Neoplasms [Mesh]
#2 (gastr*[Title/Abstract] OR stomach*[Title/Abstract] OR digest*[Title/Abstract] OR epigastr*[Title/Abstract]) AND (carcin*[Title/Abstract] OR cancer*[Title/Abstract] OR neoplas*[Title/Abstract] OR tumour*[Title/Abstract] OR tumor*[Title/Abstract] OR growth*[Title/Abstract] OR adenocarcin*[Title/Abstract] OR malig*[Title/Abstract])
#3 #1 OR #2
#4 Astragalus propinquus [Mesh]
#5 "astragalus"[Text Word] OR "radix astragali"[Text Word] OR "huang qi"[Text Word] OR "huangqi"[Text Word]
#6 kangai[Title/Abstract] OR kang-ai[Title/Abstract] OR aidi[Title/Abstract] OR ai-di[Title/Abstract] OR shenqi*[Title/Abstract] OR delisheng[Title/Abstract] OR de-li-sheng[Title/Abstract] OR qizhen[Title/Abstract] OR boerning[Title/Abstract] OR compound banmao[Title/Abstract] OR zhenqi[Title/Abstract] OR yangzheng xiaoji[Title/Abstract] OR qijiao shengbai[Title/Abstract] OR lianqi[Title/Abstract] OR cidan [Title/Abstract] OR compound tianxian[Title/Abstract] OR buzhong yiqi[Title/Abstract] OR shiquan dabu[Title/Abstract] OR guipi[Title/Abstract] OR renshen yangrong[Title/Abstract] OR danggui buxue[Title/Abstract]
#7 #4 OR #5 OR #6
#8 #3 AND #7

2 Supplementary Figures and Tables

2.1 Supplementary Figures



Figure S1. Meta-analysis results of neutropenia between the two groups



Figure S2. Meta-analysis results of anemia between the two groups



Figure S3. Meta-analysis results of thrombocytopenia between the two groups



Figure S4. Meta-analysis results of nausea and vomiting between the two groups



Figure S5. Meta-analysis results of diarrhea between the two groups



Figure S6. Meta-analysis results of hepatic dysfunction between the two groups



Figure S7. Meta-analysis results of renal dysfunction between the two groups



Figure S8. Meta-analysis results of neurotoxicity between the two groups



Figure S9. Meta-analysis results of alopecia between the two groups



Figure S10. Meta-analysis results of stomatitis between the two groups



Figure S11. Subgroup analysis of ORR via drug delivery



Figure S12. Subgroup analysis of DCR via drug delivery



Figure S13. Subgroup analysis of ORR via chemotherapy regimen



Figure S14. Subgroup analysis of DCR via chemotherapy regimen



Figure S15. Subgroup analysis of ORR via treatment duration



Figure S16. Subgroup analysis of DCR via treatment duration



Figure S17. TSA of ORR



Figure S18. TSA of DCR



Figure S19. TSA of half-year survival rate



Figure S20. TSA of 1-year survival rate



Figure S21. TSA of 2-year survival rate



Figure S22. ORR funnel plot



Figure S23. DCR funnel plot



Figure S24. QOL funnel plot



Figure S25. Neutropenia funnel plot



Figure S26.Anemia funnel plot



Figure S27.Thrombocytopenia funnel plot



Figure S28.Nausea and vomiting funnel plot



Figure S29. Diarrhea funnel plot



Figure S30.Hepatic Dysfunction funnel plot



Figure S31.Renal Dysfunction funnel plot



Figure S32.Neurotoxicity funnel plot



Figure S33.CD4^{+}/CD8^{+} ratio funnel plot

2.2 Supplementary Tables

Table S1. Subgroup analysis of outcomes (I^2＞50%)

Table S1a. Subgroup analysis of Dichotomous outcomes (I^2＞50%)

Subgroups	Number of studies	RR (95% CI)	Z	P	Heterogeneity	
					I^2	P_h
1. Half year survival rate						
Drug delivery						
Orally	4	1.12 (0.84, 1.50)	0.79	0.43	91%	<0.00001
Injection	1	1.19 (0.95, 1.50)	1.53	0.13	/	/
PBC regimens						
DDP-based chemotherapy regimen	1	1.00 (0.97, 1.04)	0.00	1.00	/	/
OXA-based chemotherapy regimen	4	1.18 (1.05, 1.33)	2.79	0.005	0%	0.68
Treatment duration						
≥8 weeks	3	1.07 (0.88, 1.29)	0.67	0.50	74%	0.02
<8 weeks	2	1.24 (1.05, 1.47)	2.53	0.01	0%	0.60
Data sources						
from study	3	1.18 (1.03, 1.35)	2.33	0.02	0%	0.47
extracted from survival curve	2	1.08 (0.80, 1.45)	0.51	0.61	85%	0.009
2. 1-year survival rate						
Drug delivery						
Orally	5	1.62 (0.99, 2.66)	1.92	0.06	85%	<0.0001
Injection	3	1.21 (0.91, 1.60)	1.33	0.18	0%	0.65
PBC regimens						
DDP-based chemotherapy regimen	2	1.12 (1.02, 1.23)	2.27	0.02	0%	0.55
OXA-based chemotherapy regimen	6	1.58 (1.27, 1.96)	4.16	<0.0001	0%	0.74
Treatment duration						
≥8 weeks	5	1.19 (1.02, 1.38)	3.60	0.0003	0%	0.42
＜8 weeks	3	1.83 (1.31, 2.55)	3.54	0.0004	0%	0.85

Data sources						
from study	6	1.51 (1.21, 1.90)	2.33	0.02	0%	0.47
extracted from survival curve	2	1.41 (1.09, 1.82)	2.14	0.03	6%	0.30
3. Neutropenia						
Drug delivery						
Orally	8	0.57 (0.41, 0.78)	3.51	0.0005	67%	0.003
Injection	12	0.74 (0.61, 0.89)	3.12	0.002	71%	<0.0001
PBC regimens						
DDP-based chemotherapy regimen	8	0.74 (0.57, 0.96)	2.31	0.02	79%	<0.0001
OXA-based chemotherapy regimen	12	0.61 (0.49, 0.77)	4.30	<0.0001	59%	0.005
Treatment duration						
≥8 weeks	17	0.67 (0.55, 0.82)	3.87	0.0001	79%	<0.00001
<8 weeks	3	0.51 (0.23, 1.11)	1.71	0.09	81%	0.005
4. Anemia						
Drug delivery						
Orally	6	0.72 (0.56, 0.94)	2.45	0.01	40%	0.14
Injection	7	0.63 (0.33, 1.23)	1.35	0.18	83%	<0.00001
PBC regimens						
DDP-based chemotherapy regimen	3	0.95 (0.84, 1.08)	0.74	0.46	0%	0.74
OXA-based chemotherapy regimen	10	0.64 (0.50, 0.82)	3.54	0.0004	42%	0.08
Treatment duration						
≥8 weeks	10	0.75 (0.57, 0.98)	2.12	0.03	63%	0.004
<8 weeks	3	0.51 (0.35, 0.73)	3.61	0.0003	0%	0.65
5. Thrombocytopenia						
Drug delivery						
Orally	8	0.60 (0.43, 0.82)	3.18	0.001	32%	0.17
Injection	12	0.70 (0.52, 0.95)	2.28	0.02	62%	0.002
PBC regimens						
DDP-based chemotherapy regimen	7	0.98 (0.86, 1.13)	0.26	0.80	0%	0.57
OXA-based chemotherapy regimen	13	0.59 (0.48, 0.73)	4.98	<0.00001	6%	0.39

Treatment duration						
≥8 weeks	14	0.76 (0.60, 0.97)	2.22	0.03	52%	0.01
<8 weeks	6	0.48 (0.35, 0.66)	4.61	<0.00001	0%	0.95

Table S1b. Subgroup analysis of Continuous outcomes (I^2＞50%)

Subgroups	Number of studies	Mean difference (95% CI)	Z	P	Heterogeneity	
					I^2	P_h
1. QOL: according to mean ± SD						
Drug delivery						
Orally	4	14.15 (5.94, 22.37)	3.38	0.0007	96%	<0.00001
Injection	2	6.48 (2.52, 10.44)	3.21	0.001	0%	0.42
Treatment duration						
≥8 weeks	4	13.17 (3.67, 22.68)	2.72	0.007	95%	<0.00001
<8 weeks	2	9.84 (7.47, 12.21)	8.13	<0.00001	0%	0.79
2. $CD3^+$ T cells						
Drug delivery						
Orally	5	14.81 (9.00, 20.61)	5.00	<0.00001	95%	<0.00001
Injection	3	5.73 (1.12, 10.34)	2.44	0.01	89%	<0.0001
PBC regimens						
DDP-based chemotherapy regimen	3	11.49 (-2.71, 25.69)	1.59	0.11	99%	<0.00001
OXA-based chemotherapy regimen	5	11.49 (6.76, 16.22)	4.76	<0.00001	93%	<0.00001
Treatment duration						
≥8 weeks	5	6.83 (3.05, 10.61)	3.54	0.0004	92%	<0.00001
<8 weeks	3	19.31 (16.03, 22.59)	11.53	<0.00001	72%	0.03
3. $CD3^+$ $CD4^+$ T cells						
Drug delivery						
Orally	5	6.08 (1.32, 10.85)	2.50	0.01	94%	<0.00001
Injection	3	6.10 (5.24, 6.97)	13.80	<0.00001	19%	0.29
PBC regimens						
DDP-based chemotherapy regimen	3	5.14 (1.13, 9.15)	2.51	0.01	90%	<0.0001
OXA-based chemotherapy regimen	5	7.25 (4.16, 10.34)	4.60	<0.00001	91%	<0.00001

Treatment duration						
≥8 weeks	5	6.98 (5.12, 8.84)	7.35	<0.00001	85%	<0.0001
<8 weeks	3	5.12 (-3.96, 14.20)	1.11	0.27	95%	<0.00001
4. Nature Killer cells						
Drug delivery						
Orally	4	3.53 (2.08, 4.99)	4.76	<0.00001	0%	0.89
Injection	2	6.46 (3.01, 9.90)	3.67	0.0002	67%	0.08
PBC regimens						
DDP-based chemotherapy regimen	1	4.14 (0.23, 8.05)	2.07	0.04	/	/
OXA-based chemotherapy regimen	5	4.63 (2.17, 7.09)	3.69	0.0002	80%	0.0006
Treatment duration						
≥8 weeks	5	4.56 (2.00, 7.12)	3.50	0.0005	80%	0.0006
<8 weeks	1	4.49 (1.39, 7.59)	2.84	0.004	/	/
5. $CD4^+/CD8^+$ T cells ratio						
Drug delivery						
Orally	7	0.46 (0.29, 0.63)	5.27	<0.00001	83%	<0.00001
Injection	3	0.29 (0.21, 0.37)	7.12	<0.00001	0%	0.99
PBC regimens						
DDP-based chemotherapy regimen	3	0.46 (0.15, 0.76)	2.92	0.003	68%	0.04
OXA-based chemotherapy regimen	7	0.39 (0.24, 0.55)	4.89	<0.00001	84%	<0.00001
Treatment duration						
≥8 weeks	7	0.39 (0.24, 0.54)	5.06	<0.00001	78%	0.0001
<8 weeks	3	0.45 (0.09, 0.82)	2.45	0.01	90%	<0.0001

Note: ORR: objective response rate, DCR: disease control rate, QOL: quality of life, CI: confidence interval, OXA: oxaliplatin, DDP: cisplatin.